GRCL

Gracell Biotechnologies Inc.

10.25 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gracell Biotechnologies Inc. stock is up 1.89% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 PUT. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Feb 20:38 21 Jun, 2024 10.00 PUT 2862 15896

About Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate. GC019F is in Phase I clinical trial for the. treatment of adult B cell acute lymphoblastic leukemia (B-ALL)